• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » St. Jude Medical closes Spinal Modulation buy

St. Jude Medical closes Spinal Modulation buy

May 4, 2015 By Brad Perriello

St. Jude Medical closes Spinal Modulation buy

St. Jude Medical (NYSE:STJ) said today that it closed its buyout of Spinal Modulation May 1, in a bid to extend its reach into the neuromodulation space.

Spinal Modulation makes the Axium device, a neurostimulator designed to treat an area of the spine called the dorsal root ganglion, which contains nerve fibers that carry pain signals to the brain.

St. Paul, Minn.-based St. Jude paid $40 million for a stake in Spinal Modulation back in June 2013, including international distribution rights for Axium and an exclusive buyout option worth up to $40 million. Today St. Jude said it will pay another $175 million when the buyout closes, expected in the 2nd quarter, with further milestones due on FDA approval and "achievement of certain revenue targets."

The buyout will make it the only medical device maker to offer radiofrequency ablation, spinal cord stimulation and dorsal root ganglion stimulation therapy solutions for the treatment of chronic pain, St. Jude said.

Privately held Spinal Modulation, which in November 2011 won E.U. approval for Axium, enjoyed backing from some of the largest companies in the medtech space, including Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ) which both participated in a $30 million Series D financing round in June 2011.

Back in December 2014, Menlo Park, Calif.-based Spinal Modulation said it closed enrollment in a U.S. pivotal study of its Axium device and later submitted a pre-market approval application with the FDA , according to a press release.

St. Jude has said it expects the Spinal Modulation buyout to dilute adjusted earnings per share by 5¢ per share for the rest of the year.

"Completing the acquisition of Spinal Modulation, Inc. is another important step forward in building momentum and accelerating sales growth across our neuromodulation product portfolio. We’re confident the Axium system will further support our goal of providing physicians multiple options to tailor treatment for patients with chronic pain," COO Michael Rousseau said in prepared remarks.

Filed Under: Mergers & Acquisitions, Neuromodulation/Neurostimulation, News Well Tagged With: Spinal Modulation, stjudemedical

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy